Cotinga Pharmaceuticals Inc. announced earnings results for the second quarter and six months ended October 31, 2018. For the quarter, the company reported net loss of $0.495 million, or $0.02 per share, compared to a net loss of $1.781 million, or $0.11 per share, for the three-months ended October 31, 2017.  The decrease in net loss during the three-month period is primarily due to decreases in Research and Development (R&D) expense and General and Administrative (G&A) expense. There was no revenue for the three months ended October 31, 2018 or in the comparative periods in the prior year. For the six months, the company reported net loss of $1.476 million, or $0.07 per share, compared to a net loss of $2.023 million, or $0.11 per share, for the six months ended October 31, 2017.  The decrease in net loss during the period is primarily due to decreases in R&D, Sales and Marketing (S&M) expense and G&A expense, offset by changes in fair value warrant liability. There was no revenue for the six months ended October 31, 2018 or in the comparative periods in the prior year.